Respiratory disease Archives

ablynx llama antigody nanobody rsv infant

News and Trends 3 May 2016

Llama Antibody Inhalation gets Positive Results for Respiratory Virus

Ablynx has gotten positive results for its candidate (ALX-0171) in Phase I/IIa trial for infants infected with a life-threatening virus – respiratory syncytial virus (RSV). Located near Ghent (Belgium), Ablynx is making advances in its Nanobody platform, based on the shorter monoclonal antibodies of llamas. Due to their small size, these Nanobodies can be used in a […]

May 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 25 Mar 2016

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma. Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics […]

March 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 24 Mar 2016

Endeavouring to Establish Europe’s Largest MedTech Fund

The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide! Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure […]

March 24, 2016 - 2 minutesmins - By Dani Bancroft

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

aspergillosis aspergillus mathias eu pet mri

News and Trends 23 Feb 2016

This new Antibody-based Imaging Technology could help fight Deadly Fungal Infections

It is estimated that up to 200,000 people globally die from fungal lung infections (Aspergillosis). Now, the EU-funded Fp7 MATHIAS project has developed an imaging technique to help doctors fight this huge killer of patients with weakened immune systems. The new test involves attaching radioactively labelled antibodies to the infecting structures formed by the fungus Aspergillus fumigatus. These fungal spores […]

February 23, 2016 - 3 minutesmins - By Dani Bancroft

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

ngs bioinformatics biomerieux illumina microbiology immunoassay

News and Trends 16 Dec 2015

Global NGS Leader’s Influence in European Bioinformatics Field is Spreading Interest in Microbiomics

BioMérieux (France) is a diagnostics tech company which has partnered with the US Bioinformatics Giant Illumina to produce a novel Microbiological genetics sequencing kit: the bioMérieux EpiSeq. BioMérieux is a worldwide leading provider of diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and reduce risk of hospital […]

December 16, 2015 - 3 minutesmins - By Dani Bancroft

blood cells transport drugs rubius therapeutics flagship erytech pku

News and Trends 14 Dec 2015

Red Blood Cells to Carry Drugs? A US Start-Up Inspired by French Biotech to Focus on Rare Metabolic Disease

Erytech (France) is working on a drug-transportation system using red blood cells. Now US Rubius Therapeutics joins Erytech on this new approach to drug delivery, backed by the huge VC in the States; Flagship Ventures. Flagship Ventures has yet again shown its comprehensive portfolio in biotech through another EU inspired Biotech start-up. Rubius Therapeutics in […]

December 14, 2015 - 3 minutesmins - By Dani Bancroft

immbio pneumonia vaccine infection heat shock proteins

News and Trends 10 Dec 2015

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Pneumonia, Meningitis and Sepsis: All these potentially fatal infections could one day be vaccinated against with Cambridge’s ImmBio and their Pneumococcal vaccine, which has now started safety & tolerability trials in the UK. ImmBio is based at the Babraham Institute, a unit of the UK’s Biotechnology & Biological Sciences Research Council (and in our Listed […]

December 10, 2015 - 3 minutesmins - By Dani Bancroft

women in biotech movers shakers 2015 biobeats

News and Trends 20 Nov 2015

Get to Know the Top 50 Women in the UK’s Biotech Scene

The Movers & Shakers Report 2015 lists 50 of the Top female Bio-Entrepreneurs… here’s a select few I found particularly impressive in the Biotech Industry! Written by Miranda Weston-Smith, the BioBeat15 report is sponsored by Horton Ruston Poole, Johnson & Johnson Innovation, MedImmune and Pfizer to celebrate what women working in bio-business have brought to […]

November 20, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us